Jun 03, 2022, 15:57
News
IR
English
Corporate Information
Other Corporate Information
Jun 01, 2022, 07:52
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
May 23, 2022, 10:25
News
IR
Swedish
Corporate Information
Other Corporate Information
May 17, 2022, 13:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
May 02, 2022, 13:30
News
IR
English
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
Swedish
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
English
Corporate Information
Other Corporate Information
Apr 29, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
Apr 19, 2022, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 12, 2022, 08:45
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 29, 2022, 13:00
News
IR
English
Corporate Information
Other Corporate Information
Mar 25, 2022, 16:45
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Feb 21, 2022, 09:15
News
IR
English
Corporate Information
Other Corporate Information
Feb 18, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 09, 2022, 10:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 09, 2022, 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se
Press releases
Follow us on Linkedin
